Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF)...
In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations Patients on tirzepatide experienced improved exercise capacity, greater weight loss and red...
Three-Stock Lunch: Eli Lilly, Transdigm, & Nvidia
Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC's ‘Power Lunch' to discuss outlooks on three stocks: Eli Lilly, Transdigm, and Nvidia.
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals.
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
The good times aren't over, but the peak of the party might be passing.
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
The market's perception of the pharmaceutical company has undeniably shifted.
KFSHRC & Lilly Collaborate in Alzheimer's Early Detection
RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU today to improve Alzheimer's patient care...
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects.
Eli Lilly and Company (LLY) Q3 2024 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q3 2024 Earnings Conference Call October 30, 2024 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President-Investor Relations Dave Ricks - Chief Execu...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespr...
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates.
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Z...
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.
Related Companies